iPS Cells & Regenerative Medicine– category –
-
iPS Cells & Regenerative Medicine Weekly Report October 4, 2026
▼ ▼ ▼ If the infographic makes you want to read the full report, please click the download button below. ▼ ▼ ▼ 📄 Weekly Report October 04, 2026 (PDF) — Download Weekly Report October 04, 2026 (PDF) — DownloadDownload 🎙 Podcast October 0... -
SonoThera’s Non-Viral RIPPLE Gene Therapy Boosts Dystrophin Expression by 290% in Macaques; Clinical Trials Slated for Mid-2027
Endpoints News USA Overview SonoThera, an Endpoints 11 2026 award recipient, is gaining traction with its RIPPLE (Remote Induction of Pulsed Pressure Lateral to Energy) non-viral gene therapy technology. Following a recent $125 million S... -
FDA Approves First AAV Gene Therapy UX111 for Sanfilippo Syndrome Type A, Offering New Hope for Pediatric Neurodegeneration
CheckRare / Rare Disease Research USA Overview The U.S. FDA has approved UX111, the first gene therapy for Sanfilippo Syndrome Type A (MPS IIIA), a rare lysosomal storage disorder characterized by pediatric dementia. This treatment deliv... -
Beam Therapeutics’ In Vivo Base Editor BEAM-302 Increases Functional AAT by 93% in AATD Patients, Transforming Long-Term Disease Risk to Carrier Status
Seeking Alpha USA Overview Beam Therapeutics' in vivo base editing therapeutic, BEAM-302, presented groundbreaking long-term follow-up data in Alpha-1 Antitrypsin Deficiency (AATD) patients. The therapy demonstrated sustained in vivo gen... -
Gut Metabolites Impact CAR-T Therapy Efficacy: Butyrate and Indoles Linked to Enhanced Long-Term Remission and Survival in 129 Patient Clinical Data
Ludwig-Maximilians-Universität München Germany Overview Researchers at Ludwig-Maximilians-Universität München published in 'Cell' that human gut metabolites significantly influence CAR-T cell therapy clinical outcomes. Analyzing 129 pati... -
CAR-T Cell Therapy Combined with Menin Inhibitors Achieves Over 90% Relapse-Free Survival in KMT2A-Rearranged Infant Leukemia
Cure Today USA Overview The combination of CAR-T cell therapy and menin inhibitors has demonstrated over 90% relapse-free survival in KMT2A-rearranged infant leukemia, a high-risk pediatric leukemia, significantly surpassing conventional... -
Meta-Analysis Integrates Safety and Efficacy of CAR T Therapy in Solid Malignancies, Lymphodepletion Enhances Response Rates
Frontiers Switzerland Overview A systematic review and meta-analysis evaluated the safety and efficacy of CAR T-cell therapy in solid malignancies, reporting an objective response rate (ORR) of 13% and a disease control rate (DCR) of 63%... -
Astellas Advances Hypoimmune iPSC Therapies for Retinal Diseases via Gene-Edited Universal Cell Technology to Overcome Immune Rejection
Astellas Japan Overview Astellas is pioneering gene-edited Universal Cell technology to develop off-the-shelf pluripotent stem cell (PSC)-derived therapies for retinal diseases, aiming to mitigate immune rejection. This technology makes ... -
IMS 2026 Reveals Real-World Data: eque-cel CAR-T Achieves 95.9% ORR in Relapsed/Refractory Multiple Myeloma
Targeted Oncology USA Overview The 23rd International Myeloma Society (IMS) Annual Meeting unveiled compelling real-world data for the commercial BCMA-targeted CAR-T cell therapy, equecabtagene autoleucel (eque-cel). In 281 relapsed/refr... -
Engineered Cord Blood CAR-NK Cells Achieve Clinical Responses in CD19+ B-Cell Malignancies with Minimized Severe Toxicity
National Academy of Engineering USA Overview Engineered cord blood-derived CAR-NK cells targeting CD19, incorporating IL-15 for enhanced proliferation and persistence, and an inducible Caspase-9 safety switch, have demonstrated clinical ...
